Targacept Inc. (NASDAQ:CBIO)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Thursday. They presently have a $3.50 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 194.12% from the stock’s previous close.
Separately, Rodman & Renshaw initiated coverage on Targacept in a research report on Thursday, June 30th. They set a “buy” rating and a $3.50 price objective for the company.
Shares of Targacept (NASDAQ:CBIO) opened at 1.19 on Thursday. The stock has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.44. Targacept has a 12 month low of $1.11 and a 12 month high of $6.04. The stock’s market cap is $14.08 million.
Targacept (NASDAQ:CBIO) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.11. Targacept had a negative net margin of 4,155.13% and a negative return on equity of 62.53%. Equities analysts anticipate that Targacept will post ($1.40) EPS for the current fiscal year.
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Targacept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Targacept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.